Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Equity-to-Asset : 0.47 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Takeda Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $46,825 Mil. Takeda Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was $98,783 Mil. Therefore, Takeda Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.47.

The historical rank and industry rank for Takeda Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

TAK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35 Med: 0.47 Max: 0.54
Current: 0.47

During the past 13 years, the highest Equity to Asset Ratio of Takeda Pharmaceutical Co was 0.54. The lowest was 0.35. And the median was 0.47.

TAK's Equity-to-Asset is ranked worse than
64.21% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs TAK: 0.47

Takeda Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for Takeda Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Equity-to-Asset Chart

Takeda Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Equity-to-Asset

Get a 7-Day Free Trial

0.38

0.37

0.40

0.43

0.46

Takeda Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial															0.46	0.46	0.47	0.48	0.47

Competitive Comparison of Takeda Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Takeda Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Takeda Pharmaceutical Co's Equity-to-Asset falls into.

Takeda Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Takeda Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Equity to Asset (A: Mar. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	47537.914	/	104423.919
	=	0.46

Takeda Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	46825.002	/	98783.156
	=	0.47

Takeda Pharmaceutical Co (NYSE:TAK) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Takeda Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

TKPHF:USA TAK:Mexico 4502:Japan 4502:Japan 4502:Japan 4502:Japan TKDA:Germany TKD:Germany TKD:Germany TAKP34:Brazil

Address

1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668

Website

https://www.takeda.com

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.